Publications by authors named "N Junker"
Based on the conservation of resources model we examined the trajectories of work-home conflict (WHC) for women and their partners in the context of the major life event of having a(nother) child and mothers' subsequent return to work. We further examined how these trajectories relate to both parents' mental health. In the context of a cohort study (the "DResdner Studie zu Elternschaft, Arbeit und Mentaler Gesundheit"-Dresden Study on Parenting, Work, and Mental Health), we examined 347 women and 223 men at three measurement points: during pregnancy (Time 1), 14 months after birth (Time 2), and 2 years after birth (Time 3; when all women had returned to work).
View Article and Find Full Text PDFSustainable production of the drug precursor tyramine by engineered Corynebacterium glutamicum.
Appl Microbiol Biotechnol
October 2024
Article Synopsis
- Tyramine is gaining attention for its use in high-performance thermoplastics, hydrogels, and as a precursor for various pharmaceuticals.
- The study successfully engineered Corynebacterium glutamicum to produce tyramine from basic nitrogen and sustainable carbon sources through metabolic engineering.
- It demonstrated that tyramine can be produced from alternative carbon sources like ribose and xylose, and stable production was confirmed in a larger bioreactor.
Utilization of orange peel waste for sustainable amino acid production by .
Front Bioeng Biotechnol
July 2024
Oranges are the most processed fruit in the world-it is therefore apparent that the industrial production of orange juice generates large quantities of orange peel as a by-product. Unfortunately, the management of the orange peel waste leads to economic and environmental problems. Meanwhile, the use of sustainable raw materials for the production of bulk chemicals, such as amino acids, is becoming increasingly attractive.
View Article and Find Full Text PDFArticle Synopsis
- LTX-315 is a novel oncolytic peptide that stimulates immune responses when injected into tumors, and this trial combined it with T-cell therapy for patients with metastatic soft tissue sarcoma.
- Six patients were treated safely with LTX-315, leading to some patients showing stable disease for 208 days and generating tumor-reactive T-cells in their blood.
- The study shows that combining LTX-315 with adoptive T-cell therapy is feasible and can stabilize disease in sarcoma patients, but further research is needed to enhance its effectiveness.
Purpose: The study evaluated safety and efficacy of olaratumab + pembrolizumab in patients with unresectable locally advanced/metastatic soft-tissue sarcoma (STS) with disease progression on standard treatment.
Patients And Methods: This was open-label, multicenter, nonrandomized, phase Ia/Ib dose-escalation study followed by cohort expansion (olaratumab + pembrolizumab intravenous infusion). Primary objectives were safety and tolerability.